Nieder Carsten, Marienhagen Kirsten, Kristensen Roy M, Sørbye Torbjørn, Hoem Lars
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø 8092, Norway; Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø 6038, Norway.
Department of Oncology, University Hospital of North Norway, Tromsø 9038, Norway.
Oncol Lett. 2016 Feb;11(2):1138-1142. doi: 10.3892/ol.2015.4005. Epub 2015 Dec 4.
Salvage radiotherapy for post-prostatectomy biochemical recurrence does not always control the disease. It would be useful to identify patients who would not benefit from radiotherapy to the prostate bed prior to making treatment recommendations. One such group of patients is those who experience continuously rising prostate-specific antigen (PSA) despite radiotherapy. The purpose of this study was to identify risk factors for continuous PSA increase and the pattern of radiological relapse during follow-up. We performed a retrospective comparison of two patient groups with PSA decline or continuous increase following salvage radiotherapy to the prostate bed. All patients received 3-D conformal radiotherapy (35 fractions of 2 Gy). Patients with continuous PSA increase were more likely to have had complete surgical resection (negative margins) and a shorter interval to radiotherapy (<24 months). However, the only statistically significant risk factor was Gleason score. Sixty-four percent of patients with a Gleason score of 9 developed continuously increasing PSA, indicating that residual subclinical cancer was not located in the prostate bed. The median time to radiological recurrence was 43 months. Isolated pelvic nodal recurrence was uncommon. Almost all patients with radiological recurrence had high-risk disease, in particular stage pT3. In conclusion, the majority of patients with biologically aggressive tumors with Gleason score 9 were not adequately treated with prostate bed radiotherapy alone. The predominant pattern of radiological recurrence was outside of the pelvis. Therefore, the problem of distant micrometastases has to be addressed.
前列腺切除术后生化复发的挽救性放疗并不总能控制病情。在提出治疗建议之前,识别那些无法从前列腺床放疗中获益的患者会很有帮助。其中一类患者是那些尽管接受了放疗但前列腺特异性抗原(PSA)持续升高的患者。本研究的目的是确定PSA持续升高的危险因素以及随访期间放射学复发的模式。我们对两组患者进行了回顾性比较,这两组患者在对前列腺床进行挽救性放疗后PSA出现下降或持续升高。所有患者均接受三维适形放疗(35次,每次2 Gy)。PSA持续升高的患者更有可能进行了完整的手术切除(切缘阴性)且放疗间隔时间较短(<24个月)。然而,唯一具有统计学意义的危险因素是Gleason评分。Gleason评分为9分的患者中有64%出现PSA持续升高,这表明残留的亚临床癌并不位于前列腺床。放射学复发的中位时间为43个月。孤立性盆腔淋巴结复发并不常见。几乎所有出现放射学复发的患者都患有高危疾病,尤其是pT3期。总之,大多数Gleason评分为9分的生物学行为侵袭性肿瘤患者仅接受前列腺床放疗并不能得到充分治疗。放射学复发的主要模式是在盆腔外。因此,远处微转移的问题必须得到解决。